ArkeaBio Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
Series A2
- Latest Deal Amount
-
$15M
- Investors
-
6
ArkeaBio General Information
Description
Developer of an agricultural bioscience technology designed to reduce methane emissions from cattle through vaccination. The company's technology produces a vaccine that targets methane-producing microbes in the digestive systems of livestock, enabling farmers and food producers to lower the environmental footprint of agriculture and mitigate global warming.
Contact Information
Website
www.arkeabio.comCorporate Office
- 500 Rutherford Avenue
- Suite 320
- Charlestown, MA 02129
- United States
Corporate Office
- 500 Rutherford Avenue
- Suite 320
- Charlestown, MA 02129
- United States
ArkeaBio Timeline
ArkeaBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series A2) | 30-Sep-2026 | $15M | Completed | Generating Revenue | ||
| 3. Early Stage VC (Series A1) | 22-Dec-2025 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 03-May-2024 | $26.5M | $38.5M | Completed | Generating Revenue | |
| 1. Seed Round | 01-Dec-2022 | $12M | $12M | Completed | Generating Revenue |
ArkeaBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | ||||||||
| Series A1 | ||||||||
| Series A | ||||||||
| Seed | 1,428,960 | $0.000010 | 8% | $7 | $7 | 1x | $7 | 8.61% |
| Pre-Seed | 2,000,000 | $0.000010 | 8% | $1 | $1 | 1x | $1 | 12.05% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ArkeaBio Patents
ArkeaBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213426-A2 | Methanogens for cell-based vaccines | Pending | 02-Apr-2025 | ||
| US-20250231566-A1 | Sun glare avoidance system (sas) in semi or fully autonomous vehicles | Pending | 12-Jan-2024 | ||
| AU-2025207062-A1 | Nucleic acid vaccines targeting methanogens | Pending | 10-Jan-2024 | ||
| WO-2025151711-A1 | Nucleic acid vaccines targeting methanogens | Inactive | 10-Jan-2024 | ||
| AU-2025206768-A1 | Protein and peptide vaccines targeting methanogens | Pending | 10-Jan-2024 | A23K20/147 |
ArkeaBio Signals
ArkeaBio Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AgriZeroNZ | Impact Investing | Minority | ||
| NYA Ventures | Venture Capital | Minority | ||
| Overview Capital | Venture Capital | Minority | ||
| Rabo Investments | Venture Capital | Minority | ||
| The Grantham Foundation | Limited Partner | Minority |
ArkeaBio FAQs
-
When was ArkeaBio founded?
ArkeaBio was founded in 2021.
-
Where is ArkeaBio headquartered?
ArkeaBio is headquartered in Charlestown, MA.
-
What is the size of ArkeaBio?
ArkeaBio has 31 total employees.
-
What industry is ArkeaBio in?
ArkeaBio’s primary industry is Other Agriculture.
-
Is ArkeaBio a private or public company?
ArkeaBio is a Private company.
-
What is the current valuation of ArkeaBio?
The current valuation of ArkeaBio is .
-
What is ArkeaBio’s current revenue?
The current revenue for ArkeaBio is .
-
How much funding has ArkeaBio raised over time?
ArkeaBio has raised $60.5M.
-
Who are ArkeaBio’s investors?
AgriZeroNZ, NYA Ventures, Overview Capital, Rabo Investments, and The Grantham Foundation are 5 of 6 investors who have invested in ArkeaBio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process